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This is an interesting challenge: to provide an overview and capture themes
of␣ the past few days, some of the “golden threads.”
BIOTECHNOLOGY’S PROMISE
The promise of biotechnology is obviously a very important thread that ran
through the entire meeting, and that term has multiple meanings. It’s not
just␣ about promise, it’s about the promises we make. It’s about public
perception—about how we as members of the public perceive what’s being
done␣ in biotechnology, in particular in terms of food. It’s about the distinction
between food on one hand and nutrition on the other, which is something
that␣ I had not fully appreciated until this meeting. And it’s about shared
responsibility and, most importantly, trust. We’ve heard that stated so many
times, but I think it’s almost impossible to overstate its importance. Obviously,
trust is a key factor.
We heard much about promising aspects of agricultural biotechnology and
about functional foods, and how we should think about differences between
putting supplements into food versus taking them as medicines as pills, and
how that is a leap that technology will offer. We have to think differently about
functional foods and nutraceuticals. Merging healthful eating with medicines
in␣ our foods is part of the promise of biotechnology—we learned a lot about
food-based products that may have medicinal capacity. Biotechnology and
agriculture offer new ways to make vaccines, more cheaply, more effectively,
and with greater capacity, actually growing medicines, or “pharming.” The
take-home message is that although agriculture and health—in particular,
public health—have always been linked, a new relationship is evolving that
requires interdisciplinary approaches and new thinking. Who should be
involved and␣ what should they be thinking about?
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We have heard about the promise of biotechnology and we have to consider
what promises we are making to the public, to producers, and to all others
involved in this endeavor; are we promising too much? Whose responsibility
is␣ it to ensure that the promises of biotechnology are actually realized?
RESPONSIBILITIES SHARED
We have shared responsibility for a number of things. First and foremost for
safety. How do we decide what counts as safe in the context of foods for health?
That is a very important question that, from the perception of the public, we
have not yet answered. How do we measure safety? We saw calculations for
what contamination might be expected from crops that cross-pollinate, but
how␣ do we measure that in a way that will provide a sense of what counts as
safe? First of all what are the criteria, and how are they measured such that
people will understand?—whoever is at the table will strongly influence what
is␣ acceptable in terms of the answers to these two points. And we heard that,
just as real estate is about location, location, location, functional foods are
all␣ about process.
We must have a process that people can support, which goes back to those
other points. Therefore, the chief issues are:
• who’s involved,
• what are the criteria,
• how do we measure safety, and
• is the process credible?
We have shared responsibilities in terms of being accountable for how this
progresses. Our promises must be realistic. Some people argue that we are over-
promising, that we are hyping—which certainly is true in stem-cell research,
for␣ instance. If we are promising more than can ever be realized, it is for reasons
that are not entirely objective—it results from attempts to obtain funding and
to␣ garner popular support, which raises political and moral issues and may
result eventually in finger-pointing.
Responsibility runs all the way through the chain, including producers,
industry, and regulators, which raises the question of whether the present
structure is up to the task of assuring this shared responsibility. Can we say
to␣ concerned individuals—which should be all of us—that we have a process,
a␣ structure, in place that will help answer these questions? Can we point to
who is accountable and why? We need to have a process in place to assess
what’s working, and what’s not, and to decide what is to be done when we
have␣ answers to those questions. It’s an evolving process.
PUBLIC PERCEPTIONS
All of this, of course, is influenced very heavily by public perceptions. “Who is
minding the store?” is a colloquial way of asking if someone is appraising issues
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of safety and accountability. Who is doing that for the public-perception issue?
We have heard a great deal about risks, not only to our own health and that
of␣ our children, but also to the environment. How do we assure that the public
understands what those risks are? To answer that question, we have to go
back.␣ We can’t tell people what the risks are until we know how to answer
these␣ questions. We are stuck way back there, before we can ever make it to
here. How can people be told what the risks are when we haven’t set criteria
for␣ risks?
Risk to health, of course, is a huge issue, and risk to children’s health
obviously falls under that as a subheading. Also people are worried about risks
to the environment at large. People want reliable information from trusted
sources, meaning credible and objective, or at least perceived as being objective.
And, from the public perspective, where is that oversight coming from?
Communication is an important factor in public perception. We know
that␣ words matter: “biotechnology” is an acceptable term whereas “genetic
engineering” and “genetically modified food” are less acceptable. Genetic
engineering and nuclear power are equal in popular acceptability. We have to
use different words or educate people differently. It was important to be told
that “we are not talking about a plate of risk factors, we are talking about a
plate of food.” In other words, we have to be careful how we use terms. Risk
factors apply to food in general, not genetically modified food in particular.
A␣ fundamentally important question is: who is responsible for getting such
messages into people’s homes, and into people’s heads? The media have
assumed that responsibility, but it is also the responsibility of the community
as␣ a whole.
Food and nutrition are not necessarily synonymous in people’s minds.
We␣ all␣ eat. One of the reasons that this issue resonates is because food is
something we all buy, sometimes grow, and we all consume. When things
apply␣ universally they tend to get particular attention. In the same way, on
the␣ health side, people get up in arms about the role of genetic information
because we all have genes and genetic testing may affect all of us.
There is a cultural aspect to food, and rituals and traditions are not to be
trifled with. When we talk about modifying food we have to consider possible
cultural implications. The take-home message here is, “Don’t mess with my
food.”
We eat for health, not to cure sickness. We don’t eat bananas because we feel
ill. We eat them because we know they’ll help keep us healthy. We should not
think that people will eat for health at the expense of other considerations,
like␣ taste. My wife expressed it like this: “I go to Whole Foods, but if what I
buy␣ there doesn’t taste good, I won’t buy it again even if it is wholesome and
organic.” Obviously, these are the most important factors. It’s got to taste good,
and it has to be safe.
Kahn
240 Integrating Agriculture, Medicine and Food for Future Health
TRUST AND ITS PRESERVATION
Clearly, a package of concepts is involved, that may be labeled under the
heading of trust. And this is where we should focus. It’s about trust at every
level, most significantly trust on the part of the public, the consumers of
genetically modified foods. If they don’t trust it, they won’t buy it. They want
to␣ be assured of effective oversight. We heard about authentication of food—
an␣ interesting concept and one that we’ve worked very hard at in terms of
medicine. Maybe it’s not always deserved, but when a medicine is on the market
we feel that it is safe, having gone through an authentication process. As foods
become more like medicines, will a similar authenticating process apply? To
preserve trust, the authentication process will have to be transparent and
public. And although it’s always better to be open, it’s not always achievable,
especially at large institutions. When the newspaper reporter calls, our first
reaction often is, “I don’t want to talk to you,” or we get defensive. But,
generally speaking, this is not the best approach. It is better to be transparent,
to be public about what we do—to communicate effectively with reliable
information. When bad things happen, it’s not appropriate to pass the buck.
We␣ must show that there’s accountability for when things go well and when
they go poorly. We can all point to events in our own lives, in our own
institutions, and in the world at large that demonstrate that when trust is
undermined it is extraordinarily difficult, sometimes impossible, to recapture
it.␣ The Starlink™ corn debacle is a good example. Popular brands of tacos are
still viewed with suspicion—that’s trust lost.
Producers need to trust that what they produce they can actually sell,
otherwise they won’t plant it. And there has to be a process by which they
feel␣ like what they are sowing is authenticated through oversight and regulatory
processes. And producers must be trusted by the public so that the latter feels
that their food is wholesome.
As already stated, trust in the regulatory and oversight processes is essential.
If the US Department of Agriculture (USDA), the Environmental Protection
Agency (EPA) and the Food and Drug Administration (FDA) have a consensus
on oversight and regulation of foods for health, than it needs to be regulated
accordingly. And gaps found in the system need to be fixed; again, Starlink™ is
a good example. The public good—or the public goods, as they are sometimes
plural—must be protected, the main considerations being human safety and
environmental safety. The regulatory process is supposed to protect what we
think is important, not as individuals necessarily, but as a collective. We also
have to trust the professionals who work in these areas. Those in agriculture
and health and nutrition and science all must be deemed trustworthy, and
equally so, for this to work. The costs of mistrust are extraordinarily high.
What is going on in Europe is an example of what we ought to hope to avoid.
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BENEFITS LOST?
If we fail to adopt new technologies, then we will forgo real benefits. That side
of the coin is often not articulated clearly enough—it’s not only about economic
costs, its about loss of benefits. If we don’t adopt technologies that could be
beneficial to health, then people will get sick and, in certain cases, die need-
lessly. Where does the balance lie? Risks need to be considered against potential
loss of benefits. If there is public mistrust, then research funding will be
affected in the long term. We heard that National Institutes of Health (NIH)
will double its budget over 5 years, but is the public sufficiently sophisticated
as␣ to understand that the Starlink™ problem, for example, is not NIH’s
responsibility? And if there’s a problem with human-subject research, could
that␣ affect funding for agricultural biotechnology? Interdisciplinary collabora-
tion will be essential—involving scientists, producers, policy makers, social
scientists, and industry—not only nationally, but also internationally. And it
must be integrated such that producers, for example, are not solely responsible
for a particular aspect.
The most important aspect is transparency in what we do: tell what we
know␣ and what we don’t know. We must communicate what the risks are, even
though many people are unwilling to accept some risk in their lives. On the
other hand, we drive our cars blithely in ways that are much more risky than
the tiny amounts of allergens that might be in our corn products. We have to
give people a real sense of what the risks and the benefits are and tell them
what we don’t know. In addition to transparency, there needs to be accountabil-
ity: who is responsible and for what? If the professions and industry won’t
exercise accountability, then Congress will step in, and we don’t want that to
happen. They are not the right people to make rules about how these things
are␣ done. It is better to be proactive to protect the public good. And if we do
that, if we keep our promises, then consumers will adopt this technology, and
funders like the National Science Foundation will continue to invest money
in␣ the research, and, hopefully, the promise of biotechnology will overtake
the␣ hype.
Kahn
